A versatile and retrievable cell macroencapsulation technology
OUR TECHOLOGY
COMPACT CELLULAR INNOVATION
Small hollow fiber device (L: 25mm W:1mm) loaded with genetically engineered myoblast cells
PRESERVING CELLULAR ACTIVITY
Biocompatible and preserves the activity of the encapsulated cells in vivo
SIMPLE, GENTLE INSERTION
Easy to insert and extract with minimal discomfort for the patient
ADVANCED THERAPY CLASSIFICATION
Reg cat: Advanced Therapy Medicinal Product (ATMP)
OPTIMAL PROTEIN DELIVERY
Optimal for long-term locoregional protein delivery including the Central Nervous System (CNS) and hard-to-reach regions of the body
SAFE BBB NAVIGATION
Safely implantable beyond the BBB, our technology targets delivery to minimize systemic toxicities and reduce adverse effects on other organs
INNOVATION BENCHMARKS
Clinical Validation and Regulatory Milestones
PROVEN CLINICAL SAFETY
Established clinical precedence with the previous product validating its feasibility, safety, tolerability, and biocompatibility.
BROAD SPECTRUM VERSATILITY
Versatility proven by successful engineering of a broad spectrum of therapeutic proteins (cytokines, antibodies, enzymes, antigens).
REGULATORY APPROVALS SECURED
Secured multiple regulatory approvals, including from the FDA and Swissmedic, for conducting a range of clinical trials in different medical fields.
SCALABLE GMP ASSURANCE
GMP validated scalable process, ensuring consistent quality, complemented by extensive patent protection, safeguarding our innovations until 2039.
Myo-P3®
The implant's protein, ipilimumab, a human IgG1 antibody, specifically targets CTLA. Approved for advanced melanoma treatment, it significantly aids in immune system modulation.
Myo-P4®
The implant produces Arylsulfatase A, addressing Metachromatic Leukodystrophy. This enzyme deficiency leads to sulfatide buildup, causing myelin sheath destruction and progressive demyelination.
Myo-P5®
The implant produces either NAGLU or SGSH to treat Sanfilippo disease.